The biggest problem I see is that the company is run by scientists. While they may know their science, they don't have a clue about markets and investors. Witness their latest news release. I believe the market has spoken with a collective "who cares" regarding its usefulness. The poster presentation didn't really show anything new regarding Brilacidin, or at least not enough to trigger a PPS increase.
We all know what the company needs to get investor interest but it appears that Nic and company think the science should be enough.
News 
Market Data 
Discover 
AI
